Tirzepatide versus Dulaglutide in T2D with ASCVD

GLP-1 receptor agonists have established themselves in recent years as a class of drugs with cardiovascular protective effects in type 2 diabetes. For dulaglutide, the 2019 REWIND study showed that the drug reduces major cardiovascular events compared to placebo—over a median follow-up period of 5.4 years, with about one-third of participants having established cardiovascular disease and the remainder having cardiovascular risk factors. Tirzepatide, a dual agonist of the GLP-1 and GIP receptors, had demonstrated a pronounced effect on blood glucose and body weight in the approval studies (SURPASS program). However, direct evidence of cardiovascular benefit in a specifically designed outcome study was still lacking.